Abstract:The emerging new lineages of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have marked a new phase of coronavirus disease 2019 (COVID-19). Understanding the recognition mechanisms of potent neutralizing monoclonal antibodies (NAbs) against the spike protein is pivotal for developing new vaccines and antibody drugs. Here, we isolated several monoclonal antibodies (MAbs) against the SARS-CoV-2 spike protein receptor-binding domain (S-RBD) from the B cell receptor repertoires of a SARS-CoV-2 convalescent. Among these MAbs, the antibody nCoV617 demonstrates the most potent neutralizing activity against authentic SARS-CoV-2 infection, as well as prophylactic and therapeutic efficacies against the human angiotensin-converting enzyme 2 (ACE2) transgenic mouse model in vivo . The crystal structure of S-RBD in complex with nCoV617 reveals that nCoV617 mainly binds to the back of the "ridge" of RBD and shares limited binding residues with ACE2. Under the background of the S-trimer model, it potentially binds to both "up" and "down" conformations of S-RBD. In vitro mutagenesis assays show that mutant residues found in the emerging new lineage B.1.1.7 of SARS-CoV-2 do not affect nCoV617 binding to the S-RBD. These results provide a new human-sourced neutralizing antibody against the S-RBD and assist vaccine development. IMPORTANCE COVID-19 is a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The COVID-19 pandemic has posed a serious threat to global health and the economy, so it is necessary to find safe and effective antibody drugs and treatments. The receptor-binding domain (RBD) in the SARS-CoV-2 spike protein is responsible for binding to the angiotensin-converting enzyme 2 (ACE2) receptor. It contains a variety of dominant neutralizing epitopes and is an important antigen for the development of new coronavirus antibodies. The significance of our research lies in the determination of new epitopes, the discovery of antibodies against RBD, and the evaluation of the antibodies' neutralizing effect. The identified antibodies here may be drug candidates for the development of clinical interventions for SARS-CoV-2.

Computational Characterization and Design of SARS Coronavirus Receptor Recognition and Antibody Neutralization.

Computational Design and Modeling of Nanobodies Toward SARS‐CoV‐2 Receptor Binding Domain

Computational Simulation of Interactions Between SARS Coronavirus Spike Mutants and Host Species-Specific Receptors.

Exploring the Efficacy of Noncovalent SARS-CoV-2 Main Protease Inhibitors: A Computational Simulation Analysis Study.

Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody

Conserved Amino Acids W423 and N424 in Receptor-Binding Domain of SARS-CoV Are Potential Targets for Therapeutic Monoclonal Antibody.

Identification and Characterization of Novel Neutralizing Epitopes in the Receptor-Binding Domain of SARS-CoV Spike Protein: Revealing the Critical Antigenic Determinants in Inactivated SARS-CoV Vaccine.

Accurate Evaluation on the Interactions of SARS-CoV-2 with Its Receptor ACE2 and Antibodies CR3022/CB6

Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development

Exploring Distinct Modes of Inter-Spike Cross-Linking for Enhanced Neutralization by SARS-CoV-2 Antibodies

Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry

Structure of Severe Acute Respiratory Syndrome Coronavirus Receptor-binding Domain Complexed with Neutralizing Antibody

Identification of a Critical Neutralization Determinant of Severe Acute Respiratory Syndrome (Sars)-Associated Coronavirus: Importance for Designing SARS Vaccines.

Structural basis of receptor recognition by SARS-CoV-2

Receptor-Based Pharmacophore Modelling of a series of ligands used as inhibitors of the SARS-CoV-2 virus by complementary theoretical approaches, molecular docking, and reactivity descriptors.

Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Computational design of scFv anti-receptor binding domain of SARS-CoV-2 spike protein based on antibody S230 anti-SARS-CoV-1

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes